Navigation Links
Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection
Date:12/10/2009

A was non-inferior to RISPERDAL CONSTA in the treatment of schizophrenia in this trial, which validates that these are both good options," said George Simpson, M.D., professor of research at Keck School of Medicine, University of Southern California and clinical investigator for the INVEGA SUSTENNA program. "The differences between the two products, such as the shorter or longer dosing interval or the need for oral supplementation, provide options for physicians to decide what will work best for an individual patient."

About the Study

The 13-week, randomized, double-blind, double-dummy trial included 1220 adults with a diagnosis of schizophrenia and a PANSS total score of 60 to 120. Participants were randomly assigned to receive INVEGA SUSTENNA (IS) plus oral placebo or RISPERDAL CONSTA (RC) plus oral risperidone for the first three weeks.

Patients assigned to IS received an initiation dosing regimen of 234* mg on day 1 and 156 mg on day 8, followed by once-monthly dosing on day 36 (78 mg or 156 mg) and day 64 (78 mg, 156 mg, or 234 mg). Additional placebo injections were administered to match RC dosing. Patients assigned to RC received their first injection on day 8, followed by biweekly injections on day 22, 36, 50, 64 and 78. This was supplemented with placebo injections to match IS dosing. The 25 mg starting dose of RC could have been increased up to 37.5 mg starting on day 36 and up to 50 mg on day 64. Patients on RC received mandatory oral risperidone supplementation from days 1 to 28. Oral supplementation was optional with subsequent dose increases.

The primary endpoint of the trial was the change in the PANSS total score versus baseline. Non-inferiority would be concluded by calculation using a 95% confidence interval (CI) based on a pre-specified change in total PANSS score. Secondary efficacy measures included change from baseline for Clinical Global Impression-Severity (CGI-S) and Personal and Social Pe
'/>"/>

SOURCE Janssen(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Reportlinker.com announces that a new ... Global Heart Valve Repair and Replacement ... About Heart Valve Repair and Replacement ... which control the flow of blood during the ... diseases such as valvular stenosis, valvular insufficiency or ...
(Date:8/27/2014)... -- Reportlinker.com announces that a new market research report ... Eastern Europe 2014 http://www.reportlinker.com/p02312454/Baby-Food-Eastern-Europe-2014.html ... a new report by ERC that analyzes the Baby ... , key segments, features & developments, future projections ... which are currently affecting the industry. Furthermore, it profiles ...
(Date:8/27/2014)... , Aug. 27, 2014 North American lighting ... prestigious R&D 100 Award for the new OSRAM ITOS ® ... LED-based white light module for microscopy, endoscopy and surgical head ... with significantly higher efficacy and lamp life. "We,re ... one of the most innovative new technologies of the past ...
Breaking Medicine Technology:Global Heart Valve Repair and Replacement Market 2014-2018 2Global Heart Valve Repair and Replacement Market 2014-2018 3Global Heart Valve Repair and Replacement Market 2014-2018 4Baby Food Eastern Europe 2014 2Baby Food Eastern Europe 2014 3Baby Food Eastern Europe 2014 4Baby Food Eastern Europe 2014 5Baby Food Eastern Europe 2014 6Baby Food Eastern Europe 2014 7Baby Food Eastern Europe 2014 8OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3
(Date:8/27/2014)... 27, 2014 Beginning in September, K9 ... (DOG) as an interactive, fun way for daycare dogs ... to all K9 Dog Park Doggy Daycare clients who bring ... per week. Clients will be able to watch their ... The dogs that compete in D.O.G. will win prizes as ...
(Date:8/27/2014)... Aug. 26, 2014 (HealthDay News) -- Health care workers ... gear to keep them safe from being infected with ... study shows. While the study was conducted before ... spring, its findings are confirmed in statistics released Monday ... health agency reported that an "unprecedented" number of health ...
(Date:8/27/2014)... microGUNE, the Co-operative Research Centre into Microtechnologies, ... to generate innovative solutions based on microtechnologies ... industry and life sciences, among others. IK4-Ikerlan, ... are collaborating with CIC microGUNE on this ... by the Etortek 2013-2014 programme of the ...
(Date:8/27/2014)... This news release is available in German . ... need for medical agents to treat metastatic tumors. In case ... cancer that is often detected late, 95% of the patients ... amcure develops tumor therapeutic agents that might reduce this mortality ... has now received a total of EUR 5 million from ...
(Date:8/27/2014)... When a friend invited Misty Mozejko to join a ... the beginning of a new way of life and a new ... “I knew I needed to turn my life around but I ... Misty stuck with the program. “It was so difficult,” she laughs. ... my comfort zone, but between the boot camp and some good ...
Breaking Medicine News(10 mins):Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 2Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 3Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 4Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 2Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 3Health News:Microtechnologies for driving forward mobility and human health 2Health News:Preclinical development of tumor therapeutic agent starts 2Health News:Whitby Fit Body Boot Camp Releases Gift Certificate for Two-Week Complimentary Access to Fitness Boot Camp 2Health News:Whitby Fit Body Boot Camp Releases Gift Certificate for Two-Week Complimentary Access to Fitness Boot Camp 3
... By Steven Reinberg HealthDay Reporter , MONDAY, Jan. ... with a small increase in the risk of heart attack, ... in Ohio looked at seven trials involving Pradaxa that included ... data from published clinical trials to tease out a pattern ...
... HealthDay Reporter , MONDAY, Jan. 9 (HealthDay News) -- ... new research that finds losing a loved one can increase ... a significant other,s death, heart attack risk was 21 times ... nearly 2,000 heart attack patients. And within the first week ...
... , MONDAY, Jan. 9 (HealthDay News) -- Nicotine patches and ... therapy" -- don,t help many smokers kick the habit ... This conclusion is based on results of several surveys ... who used nicotine replacement therapy (NRT) did not gain any ...
... Randy Dotinga HealthDay Reporter , MONDAY, Jan. 9 ... used by people trying to quit smoking could serve an ... older patients. The research is preliminary and only involved ... While they,re available over the counter, patches may cost several ...
... -- A 2010 outbreak of Legionnaires, disease in Wisconsin ... hospital lobby, according to a study published in the ... , the journal of the Society for Healthcare Epidemiology ... was detected among eight people in southeast Wisconsin, state ...
... (HealthDay News) -- Waiting up to a year to treat ... not harmful, but waiting many years to get blood pressure ... In the study, published online Jan. 9 in the ... University of Chicago suggested that the one-year delay could give ...
Cached Medicine News:Health News:New Blood Thinner Linked to Higher Heart Attack Risk 2Health News:New Blood Thinner Linked to Higher Heart Attack Risk 3Health News:Grief Is a Real Heartbreaker, Study Finds 2Health News:Grief Is a Real Heartbreaker, Study Finds 3Health News:Nicotine Patches, Gums Won't Help Smokers Quit Long-Term: Study 2Health News:Nicotine Patches, Gums Won't Help Smokers Quit Long-Term: Study 3Health News:Could Nicotine Patches Help Stave Off Memory Loss? 2Health News:Could Nicotine Patches Help Stave Off Memory Loss? 3Health News:Legionnaires' disease outbreak linked to hospital's decorative fountain 2Health News:Short Delay in Treating Blood Pressure Safe for Diabetics: Study 2Health News:Short Delay in Treating Blood Pressure Safe for Diabetics: Study 3
... Antibody (IgM) Test is an ... quantitative detection of antibodies to ... is used as an aid ... thrombosis in individuals with systemic ...
The 8500 is an extremely reliable portable pulse oximeter, requiring no periodic maintenance or calibration....
Rad-5v signal extraction pulse oximeter™...
... The 8500 Digital Handheld ... universal tool for patients monitoring ... continuous monitoring. As the first ... as a benchmark for durability ...
Medicine Products: